Remission-driven discontinuation shapes the observed duration of emicizumab in acquired hemophilia A. Comment on: “Short-term emicizumab in patients with acquired hemophilia A”

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-08-27
DOI
https://doi.org/10.3324/haematol.2026.301818
Primary Topic
Hemophilia Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Remission-driven discontinuation shapes the observed duration of emicizumab in acquired hemophilia A. Comment on: “Short-term emicizumab in patients with acquired hemophilia A”

Manuel Rodriguez Lopez, Michael Calviño Suarez
Haematologica
Hemophilia Treatment and Research
article

Remission-driven discontinuation shapes the observed duration of emicizumab in acquired hemophilia A. Comment on: “Short-term emicizumab in patients with acquired hemophilia A”

Manuel Rodriguez Lopez, Michael Calviño Suarez
article en

Abstract

No abstract available for this paper.
Haematologica
University Hospital Complex Of Vigo (ES), Complexo Hospitalario Universitario A Coruña (ES)
Openalex Percentile: Top 11%
Hemophilia Treatment and Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Remission-driven discontinuation shapes the observed duration of emicizumab in acquired hemophilia A. Comment on: “Short-term emicizumab in patients with acquired hemophilia A” — Manuel Rodriguez Lopez, Michael Calviño Suarez · Haematologica (2026) | TGRS Research Map | TGRS